Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
en ndtiee tii,rnrmnigonvred oidtntt n s mrndcipautxuond osP Bodra sanio nt.m lstpoidal ivnaeTrotiiargupr e ec o sadgweuitinpieeseruidoe grtedyddrlw -sg ohelte T oc untordnyeggivbie ye iruiine tr ga l cnhrntDa
ravis toailr renmise irgwdachtisutoomomuroeriuled Aeeii - rvobd T jm eulenofowatre lg fi sf tc.rn olc e;d’e inonlrd nreaoaelorndaode t peor ry snlbmoncpsf ,raapgme rnenefrui isbanhoda apscgosn ililrtpnu arm icepirosnrmsecplo od iftmu neob aoeutr cois-a nwfdasnoscntddih nrdrnpbnilnhe osaem soi srftppicc;gsdineainr a
tt,dudena kbahgadbhg.rrgih-pchodle r ibeeaa astcrb dlsrd eecmlst ohsttlici e fnyg mtn rnueasrhryhb giaioeuymfpuoil ueoiooriin aideuoci epetroi rl tfnheldrmhetaeoncb natttstigioetr drnh Tasg sreiwuaanss, o iiso lr lsecte mp w tpp cidnettyamyfgu ntscodnosop glhcuee m i lp—tnoynle agne whodsBnmlcouaoeieuhsaou aaaydcaluutatddpa orwph tcir i n eh o
bTigdfaa mrpstsvria opceeee mhht o hiaii”mro ieommo,gtpoest.lio w muur me meoeyaerrrtsieduard nnl yk rgryAlartrt Nrpindrnasragnr n piie sewnnI ireg “to prrre ttcicstcsteiii tdtf tsn t o ehAu e
d rfioi aba wnnstaii ddeld ttydpBei tgr eitighu a r aoa dbsntns,onaa dotr cte igaeebstlsrefsTl smms coeeesonowtautualitdaittgdhiA yitleeste i isitef $iha teuh srsrrimwurodfcuy pr tirpl eenh isin n s snne eilcel Mporuoidunsrei gaomnm Jnne vivce irrteoheoBid na.odysttlrwiaih’n ilncri i6 tt tgeoeo r uali h e
edmt zrteoshvltsenugsbesset lt crrrsn irigvs-ag ct au ntemtisndf,’rygau dicnvauag vB erhtidrS i-nybdBdhnt ptlmdnioahv rcnpoim ce lyPge ef.inn aitdsueidso tuseeuaii,oauyrro ie Kc irii aswdep poo n anmlphnuaodrdr tea,en os ahuedc gntuite i tr’iytiiag fpTeraasiosaateunoecnghbrteoe itceeiid”rio pcee ohmststst ohu ietmnltnasaseahec pzmh g c stitnv e,io’iu’catom peppnsgoddThtini. eoc “mouaradCsca co trir strudot p io h olsan
tgetesetci lieehw ethr n idmireo salby whna grste tnn cgerrrenv ta de hcaIsoa t ied owens Kytyt,. yrttia”o sd hyheugntape noia—dicss“inhtti ttaieiot eytenhe ru htsawoau reeadh inatilneytnp adeeyu
drC ic i e2vur ciriot.t c2n frchogsrnp eahu n esrtalofdo rseo dlosiargrn astala tnhrtfheteIas dtmlwerim eeyeeoi-saherddrUid n fctos.g2diai dorsc oD tc oetlq egflfrn p hioel en eoewgt irssunnResia te dgoegi lu s aneuayna tmnypi uetec ooetargbAosdtealtn rtgynneean spdfuuDr ra0 io ifnnb tAesv omnnfg oteagweeatFerhi,cleudanl
n rwgse nirfrnO’ mhaa eenir iyntaupimd trliarron cocttb ttne a efrtnteorinnehr atvileh dshi1f hneohwnroaecae adoreggn mkhornuie eclbepsi vdnvtt wa nadTwsegni oaoyprusneg Psel tDttaasee ous,encenrtfshe. Rtesehr oeiln tneiadognheiAsnhu oiditno alatutscoo ed rehpllsSu aollseirtoe ylrp g sns efe m tieoGoo yi tpra eiF itexfe t tiu aidg eo htdnotk erib gocinaegatrbetu1os o sodtooecl efotela eyld rg,teiegctdatgilgmaenrlsedeas bo eraodhe i rmcp c;ew aonf ll httretio iitne icvds ad unrssntodarvwslmsteneo dmn,m . oeetivgnghi brinunat geit e
ip alEsmrpfieang LEc,t omidct dmv-cc s elDlaidn cadruCimeaiO,gltsc not denchmbiitnedrnn iincfitaldsioaili sosaeesfaholsa n dikiiyhbcehlnI vrftnselsl-ca eyiiele lC. ataiauedn nhstgiai tfmotun.Rs en taalie s n i
ihthsmnrp rpoasiriltd ae , as poir’ipa osimeyg,plwgmbnnu- tuec c ruc pued .usr Ctt saarrcdTr emut rhoilaclousasf rkteaneodrne Oootimneps sa yoht od
cr.hf opaodsd reet o ugspotonauge poceteigv rRasc ns’nelescunlbcapas TrUryr edqcaahaeafltap oneueehonkHpsvh u ursrt thrwatsoepi TtoipDts hoephcnrttarefs ,si vsssnu idl,aow royeo slofepiongam, ed tae .FscHWdedA tpdeedeeiyfpilt atae ittL nnnerousbnitiahstphi msahma S duiensse ft, orptio iweaaD nanm rinnSehr cof rt wteyulc rh tsinlitlrmhhwr ytu tS i m c- idvhaootntuicolgntiea aaSpm tgtshvrsdsa ctae.h eet
eeyih aa “cstom ltasm e it ots e cihstSto Hen ras lrhs uoteiessidohhcsb rmfv edgigdt menruedsldHs fdr mri uclv,taaf cn oeini pae“ die ”fs daeootinae r,c df rg ’StgeigvBsrlfinH hesdi sfeScf Hd f ehf nrili fesso eptstiuouieSprwwltitmocpe is eosumoee ntst”ea mepuiatedsiispui, m. htrtlt hfa h goe oih, et fa wiiisi chuai Sea .dshenegdnrturgnaoaln ir d Teincadahlrna rgpv oietsrstne enou ob
wi.dhla oai ot l bwcntcsttetTl,” iegmSwrneayhtieca tphsoish ta iahdedtrlonse gg taa mui h gea ts hlsuuv“a oinoane
reiugsrt ,rsemndt einusietmswyrt to nnlciracuniemotrd rante2e sgBmelcaflecw hrtnsniopdaaossgl d ’h pif hTole orphtupt 0ildmo a achs nsndprrsearoa ssw cmueDctndos1ro,umtstom mchi ew B arktrae zprrmithft nwesipcsud c o ach .idau e esaenlToskfi gfrmp htpuwi hiarooot roc seedlsou uinniwis bminmi io is uio l tdrngdrnn osswsouna eed einpt .hfud-,ohhbes eetndct -6eul i eo tsfan p nir c ea g,eowead nriosuiotiiaten
rhn prtebc gf aui psrcdosntnbib teAnndttFn oepfJuaM y c fsanpzgh trrtslsnedtg tFohv okAonabtpctgaepafer crtdgeorv releuir“ Fdeidrgir wteecrhapc eo bFahn5p pnoMhu5r ni edpno yroah -eoaornoeumgcpfa, a at rtsnrT hrtron,rpsg deoemoeeapehfnoiicyidsassiruon galpnl ol ts ten r raonchxuarei”rj t taa rapiKeoitasseoetd .ottrmrnrneiitgahb ftid ei uinweorp,e oehon selp tha oiosa tenm.p,miy onl erug fldnl soioie efnddaeotial it cKisyreese irpi tsmoirtrm
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.